Summary: In 192 adults with type 2 diabetes managed at a single ambulatory clinic, multifactorial care delivered by a multidisciplinary team (combined medication optimisation and lifestyle support) was compared with standard care over a mean of 11.9 months. The intervention produced a modest but statistically significant reduction in HbA1c (mean difference -0.36%, 95% CI -0.54 to -0.19) and a favourable adjusted eGFR difference (+3.93 mL/min/1.73m2), alongside improved blood-pressure target attainment.
PICO Summary
| Element | Detail |
|---|---|
| Population | 192 Emirati adults with type 2 diabetes attending a single ambulatory healthcare clinic in the United Arab Emirates; randomised controlled trial with participant blinding; mean follow-up 11.9 months. |
| Intervention | Multifactorial care by a multidisciplinary team (individualised diabetes medication optimisation plus lifestyle support: diet, exercise, adherence), reinforced at 3-, 6- and 9-month visits. |
| Comparison | Standard routine diabetes care at the same clinic. |
| Outcome | HbA1c mean difference -0.36% (95% CI -0.54 to -0.19, P<0.01). Adjusted eGFR difference +3.93 mL/min/1.73m2 (95% CI 1.27 to 6.58, P<0.01). LDL-cholesterol mean difference -0.14 mmol/L (95% CI -0.27 to 0.001, P<0.03). HbA1c <7% reached in 40.4% (intervention) vs 31.6% (control); blood-pressure target attainment rose from 38.3% to 51.1% (intervention) vs 34.7% to 36.7% (control). Gains occurred despite reduced diabetes medication use. No ARR/NNT for hard cardiovascular endpoints was reported. |
Multifactorial vs standard care in type 2 diabetes
RCT · type 2 diabetes · 11.9 months
Team-based multifactorial care gave a modest but significant HbA1c reduction and favourable eGFR over one year, even with less medication. Single-centre, soft endpoints, no hard outcomes.
Expert Commentary
This trial is best read as supportive but modest. A team-based, multifactorial approach was associated with a statistically significant HbA1c reduction, yet the -0.36% mean difference sits below the threshold usually regarded as clinically decisive, and the favourable eGFR and blood-pressure signals, while consistent in direction, were measured over a single year. The finding that glycaemic and renal markers improved despite reduced medication use is plausible if lifestyle optimisation and deprescribing were handled carefully, although it should be interpreted as a process signal rather than proof of disease modification, since hard cardiovascular and renal endpoints were not powered or reported. The principal limitation is that this was a single-centre study in one national population, so generalisability beyond that setting is uncertain. The care intervention could not be blinded to the treating team, and unblinded delivery may inflate soft outcomes such as target attainment. No industry or manufacturer sponsorship was apparent, which is reassuring, and no implausibly large effects were claimed. Can I use this with my patients? Cautiously yes, for organising structured multidisciplinary diabetes care in a clinic setting, but not as evidence that this specific protocol prevents complications. Larger, multicentre, longer trials with hard endpoints are needed before firmer claims are made.
References
El-Deyarbi M, Ahmed L, King J, Adi ZS, Al Juboori A, Mansour NA, et al. Impact of multifactorial interventions with medication and lifestyle optimization on patients with type 2 diabetes: a randomised controlled trial. PLoS One. 2025;20(7):e0327211. doi:10.1371/journal.pone.0327211
